Skip to content
Project Directory
  • Français
Donate Now
  • Français
  • About
    • What We Do
    • Leadership
    • Team
    • Publications
    • Careers
  • Diseases/Disorders
    • One Brain
    • ALS
    • Alzheimer’s
    • Autism
    • Brain Cancer
    • Brain Injury
    • Epilepsy
    • Mental Illness
    • Multiple Sclerosis
    • Parkinson’s
    • Stroke
    • Other
  • Research
    • Programs
    • Funding Opportunities
    • Program Partners
    • Announcements
  • Impact
  • Ways To Give
    • Your Impact
    • How You Can Help
    • Events

Funded Grants

Back to results

Magnetic resonance imaging to compare the abilities of non-selective and selective huntingtin suppression technologies to prevent brain pathology in Huntington disease

Project Overview

Huntington disease (HD) is an inherited disorder that causes brain cells to die and impacts approximately 1 in 7000 Canadians. A person with HD experiences worsening psychiatric, motor, and memory impairments. While there is still no cure for HD, gene therapies have shown promise and entered clinical trials with the goal of lowering the huntingtin protein responsible for the symptoms of HD. In 2021, a phase III clinical trial was stopped early because of poor drug performance, a devastating setback for the HD community. The goal of this project is to use a mouse model that reproduces the clinical features of HD and advanced magnetic resonance imaging technologies to understand the impact of gene therapy on whole brain anatomy and hopefully shed light on why the clinical trial failed. In addition, we will explore another strategy for therapy, selectively lowering only the pathogenic huntingtin protein while keeping the non-pathogenic huntingtin protein. We will also determine whether the timing of the therapy affects the disease progression and if females and males respond differently to treatment.

In collaboration with world-renowned experts in gene therapy for HD, this study has the potential to transform our understanding of the mechanisms of the disease and for testing therapies. Because the imaging technology used in this project is the same as what is used clinically to diagnose HD, our findings in mice can be rapidly translated to use in humans and will inform future clinical trials. Determination of the best strategy to prevent or reverse HD-associated brain pathology will lead to improved therapies for HD patients.

Principal Investigator

Lindsay Cahill , Memorial University

Partners and Donors

Azrieli Foundation

Project Ongoing

Magnetic resonance imaging to compare the abilities of non-selective and selective huntingtin suppression technologies to prevent brain pathology in Huntington disease

  • Program Type

    Capacity building grants

  • Area of research

    Neurodegeneration

  • Competition

    Future Leaders in Canadian Brain Research

  • Province

    Newfoundland and Labrador

  • Start Date

    2022

  • Total Grant Amount

    $100,000

  • Health Canada Contribution

    $50,000

Contact Us

1200 McGill College Avenue
Suite 1600, Montreal, Quebec
H3B 4G7

The offices of Brain Canada Foundation are located on the traditional, ancestral territory of the Kanien'kehá:ka Peoples, a place which has long served as a site of meeting and exchange amongst nations.

+1 (514) 989-2989 info@braincanada.ca

Playing with Marbles Podcast

Join us and take a journey to the real last great frontier – the brain.

Listen

Subscribe to Brain News

Receive our monthly electronic newsletter with updates on funded projects, upcoming events and breakthroughs in brain research.

Sign up

© 2023 Brain Canada Foundation

Registration number: 89105 2094 RR0001

  • Terms and Conditions
  • Privacy Policy

Design by Field Trip & Co